Novartis is a global healthcare company headquartered in Basel, Switzerland, focused on reimagining medicine to improve and extend people's lives. Leveraging innovative science and digital technologies, Novartis creates transformative treatments in areas of high unmet medical need. The company's portfolio includes innovative medicines across various therapeutic areas, including oncology, immunology, neuroscience, cardiovascular, and respiratory diseases. Novartis is committed to research and development, aiming to deliver breakthrough therapies that address some of society's most challenging healthcare issues.
The Novartis global headquarters serves as the central hub for strategic decision-making, corporate governance, global research and development leadership, and core corporate functions.
The Novartis Campus in Basel is renowned for its modern architecture, designed by world-class architects, featuring state-of-the-art research laboratories, collaborative office spaces, and sustainable green areas. It's often referred to as a 'city of knowledge'.
The work culture at the Novartis HQ emphasizes innovation, collaboration, scientific excellence, and a 'curious, inspired, and unbossed' mindset. It fosters a diverse and inclusive environment dedicated to advancing healthcare.
Basel's strategic location in the heart of Europe, with a rich history in pharmaceuticals and life sciences, provides Novartis with access to top talent, research institutions, and a strong industry network.
Novartis maintains a significant global footprint, with operations in approximately 140 countries worldwide. Key functions supported globally include research and development (with major research centers in Switzerland, the US, and China), manufacturing (with a network of production sites), and commercial operations tailored to local market needs. This widespread presence enables Novartis to conduct global clinical trials, access diverse scientific talent, and deliver its innovative medicines to patients across the globe.
Lichtstrasse 35
Basel
Basel-Stadt
Switzerland
Address: One Health Plaza, East Hanover, NJ 07936-1080, USA
Critical for managing Novartis's activities in the largest pharmaceutical market globally, including bringing innovative medicines to American patients, conducting clinical trials, and engaging with regulatory authorities like the FDA.
Address: Elm Park, Merrion Road, Dublin 4, Ireland
Acts as a key strategic hub for global operations, leveraging Ireland's skilled workforce and business environment to support Novartis's worldwide activities and supply chain.
Address: Novartis Healthcare Pvt. Ltd., NSL SEZ (Arena), Plot No 6, Survey No 1, IDA Uppal, Hyderabad, Telangana 500039, India
Leverages India's talent pool to provide critical support for Novartis's global R&D and commercial operations, contributing to efficiency and innovation across the company.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Novartis' leadership includes:
Novartis has been backed by several prominent investors over the years, including:
Novartis has experienced notable executive transitions in the past 12 months, including the announcement of a new Chief Financial Officer, a new Chief Strategy & Growth Officer, and changes in operations leadership, reflecting its ongoing strategic evolution.
Discover the tools Novartis uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Novartis commonly uses the firstname.lastname@novartis.com email format for its employees. While variations may exist for specific departments or legacy systems, this is the most prevalent structure.
firstname.lastname@novartis.com
Format
jane.doe@novartis.com
Example
90%
Success rate
Novartis Press Release • May 23, 2024
Novartis announced positive results from the Phase III PSMAfore trial, where Pluvicto™ showed a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) after treatment with an androgen receptor pathway inhibitor (ARPI), prior to receiving taxane-based chemotherapy....more
Novartis Press Release • April 23, 2024
Novartis announced strong Q1 2024 results with net sales growing 10% (cc, USD) and core operating income up 20% (cc, USD). The company raised its full-year 2024 guidance for both net sales and core operating income, reflecting continued strong performance across key growth drivers....more
Novartis Press Release • April 16, 2024
Novartis announced the successful completion of its voluntary public takeover offer for MorphoSys AG, a biopharmaceutical company developing innovative cancer treatments. The acquisition strengthens Novartis's oncology pipeline, adding pelabresib, a late-stage BET inhibitor for myelofibrosis, and tulmimetostat, an early-stage dual inhibitor of EZH2 and EZH1 for solid tumors or lymphomas....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Novartis, are just a search away.